Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
TAVR
MedTech
FTC outlines antitrust case against Edwards' JenaValve deal
In its opening statement, the FTC said Edwards would control the only two potential TAVR systems designed to treat aortic regurgitation.
Conor Hale
Nov 25, 2025 3:10pm
At ESC 2025, researchers call for earlier, simpler TAVR
Aug 29, 2025 1:00pm
FTC aims to stop Edwards' acquisition of JenaValve
Aug 7, 2025 11:33am
Abbott eyes structural heart gains after Boston Scientific exit
Jul 17, 2025 1:00pm
Boston Scientific pulls Acurate TAVR implants from market
May 28, 2025 11:01am
FDA approves Edwards TAVR for patients before they show symptoms
May 1, 2025 12:56pm
